These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23430361)

  • 1. Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging.
    Cabrera R; Husain Z; Palani G; Karthikeyan AS; Choudhry Z; Dhanalakota S; Peterson E; Ananthasubramaniam K
    J Nucl Cardiol; 2013 Jun; 20(3):336-43; quiz 344-5. PubMed ID: 23430361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.
    Partington SL; Lanka V; Hainer J; Blankstein R; Skali H; Forman DE; Di Carli MF; Dorbala S
    J Nucl Cardiol; 2012 Oct; 19(5):970-8. PubMed ID: 22565239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.
    Parker MW; Morales DC; Slim HB; Ahlberg AW; Katten DM; Cyr G; Mathur S; Ardestani A; Barmpouletos D; Iyah GS; Borer SM; Heller GV
    J Nucl Cardiol; 2013 Apr; 20(2):185-96. PubMed ID: 23188626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results.
    Janvier L; Pinaquy J; Douard H; Karcher G; Bordenave L
    J Nucl Cardiol; 2017 Feb; 24(1):34-40. PubMed ID: 26542990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily Caffeine Consumption Is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
    Posch MI; Kay MD; Harhash AA; Huang JJ; Krupinski EA; Abidov A; McMillan NA; Kuo PH
    J Nucl Med Technol; 2020 Mar; 48(1):73-76. PubMed ID: 31604901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.
    Thompson RC; Patil H; Thompson EC; Thomas GS; Al-Amoodi M; Kennedy KF; Bybee KA; Iain McGhie A; O'Keefe JH; Oakes L; Bateman TM
    J Nucl Cardiol; 2013 Apr; 20(2):214-21; quiz 222-6. PubMed ID: 23233371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial.
    Ballany W; Mansour K; Morales Demori R; Al-Amoodi M; Doukky R
    J Nucl Cardiol; 2014 Jun; 21(3):496-502. PubMed ID: 24519563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.
    Salgado-Garcia C; Jimenez-Heffernan A; Lopez-Martin J; Molina-Mora M; Aroui T; Sanchez de Mora E; Ramos-Font C; Rivera de Los Santos F; Ruiz-Frutos C
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1906-1914. PubMed ID: 28547175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.
    Palani G; Husain Z; Salinas RC; Karthikeyan V; Karthikeyan AS; Ananthasubramaniam K
    J Nucl Cardiol; 2011 Aug; 18(4):605-11. PubMed ID: 21541818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
    AlJaroudi WA; Alraies MC; Cerquiera MD; Jaber WA
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):341-8. PubMed ID: 23208701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials.
    Rangel MO; Morales Demori R; Voll ST; Wassouf M; Dick R; Doukky R
    J Nucl Cardiol; 2015 Oct; 22(5):1008-18. PubMed ID: 25500799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
    Amer KA; Hurren JR; Edwin SB; Cohen G
    Pharmacotherapy; 2017 Jun; 37(6):657-661. PubMed ID: 28475259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.
    Iqbal FM; Hage FG; Ahmed A; Dean PJ; Raslan S; Heo J; Iskandrian AE
    JACC Cardiovasc Imaging; 2012 Oct; 5(10):1014-21. PubMed ID: 23058068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands].
    Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S
    Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.
    Kwon DH; Cerqueira MD; Young R; Houghtaling P; Lieber E; Menon V; Brunken RC; Jaber WA
    J Nucl Cardiol; 2010 Oct; 17(5):853-7. PubMed ID: 20414756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of regadenoson positron emission tomography stress testing in orthotopic heart transplant patients.
    Lazarus JJ; Saleh A; Ghannam M; Aaronson K; Colvin M; Pagani F; Koelling T; Corbett JR; Weinberg RL; Murthy VL; Konerman MC
    J Nucl Cardiol; 2020 Jun; 27(3):943-948. PubMed ID: 30483958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience.
    Pape M; Zacho HD; Aarøe J; Eggert Jensen S; Petersen LJ
    Scand Cardiovasc J; 2016 Jun; 50(3):180-6. PubMed ID: 26956081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of regadenoson stress testing in patients with pulmonary hypertension.
    Moles VM; Cascino T; Saleh A; Mikhova K; Lazarus JJ; Ghannam M; Yun HJ; Konerman M; Weinberg RL; Ficaro EP; Corbett JR; McLaughlin VV; Murthy VL
    J Nucl Cardiol; 2018 Jun; 25(3):820-827. PubMed ID: 27896702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm.
    Iskander F; Iskander M; Gomez J; Doukky R
    J Nucl Cardiol; 2021 Jun; 28(3):967-977. PubMed ID: 31144225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial.
    Rangel MO; Demori RM; Doukky R
    Am J Ther; 2013; 20(6):622-9. PubMed ID: 24100259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.